💡 Their goal is to adapt Eukarÿs’ C3P3 technology for gene therapies.
💰 This collaboration aims to lower manufacturing costs for adeno-associated viruses (AAVs).
👩🔬 Généthon will share its expertise in AAV vector design.
🌟 Both companies believe this partnership can make gene therapies more affordable and accessible for patients.
Introduction:
The article discusses a strategic partnership between Généthon and Eukarÿs aimed at reducing manufacturing costs related to gene therapies. Généthon, a non-profit organization, specializes in gene therapies for rare diseases, while Eukarÿs focuses on enhancing biomanufacturing yields through innovative technology.
- Généthon and Eukarÿs have formed a partnership to adapt Eukarÿs’ C3P3 technology for use with adeno-associated viruses (AAVs), an important aspect of gene therapy manufacturing.
- Eukarÿs’ C3P3 is an engineered enzyme that significantly boosts mRNA synthesis, enabling a 5- to 7-fold increase in production yields in mammalian cells.
- The collaboration aims to leverage Généthon’s expertise in AAV vector design and production, which has already contributed to successful clinical trials for various gene therapies.
- Both companies highlight the potential of the partnership to facilitate more efficient production conditions and significantly reduce manufacturing costs for gene therapies.
- Experts suggest that this technological advancement could lead to more affordable gene therapies for patients suffering from serious diseases.
Conclusion:
The partnership between Généthon and Eukarÿs represents a significant step towards making gene therapies more accessible through cost-effective manufacturing solutions. By adapting C3P3 technology for AAVs, the collaboration may enhance production efficiency and contribute to the development of more affordable treatments for rare diseases.
